Skip to content
✕

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Heart icon (animated) heart icon (static)
Our Stories
Our Company
Explore more Johnson & Johnson sites:
Australia
A graphic of the flag of Australia alt
Argentina
A graphic of the flag of Argentina alt
Brazil
A graphic of the flag of Brazil alt
Canada
A graphic of the national flag of Canada alt
Consumer Health
Janssen
MedTech
Chile
A graphic of the flag of Chile alt
China
A graphic of the national flag of the People's Republic of China alt
Colombia
A graphic of the national flag of Colombia alt
Costa Rica
A graphic of the national flag of Costa Rica alt
Czech Republic
Ecuador
A graphic of the national flag of Ecuador alt
France
Germany
A graphic of the flag of Germany alt
India
A graphic of the national flag of India alt
Japan
A graphic of the national flag of Japan alt
Mexico
A graphic of the flag of Mexico alt
New Zealand / Pacific
A graphic of the flag of New Zealand alt
Paraguay
A graphic of the flag of Paraguay alt
Peru
A graphic of the flag of Peru alt
Philippines
A graphic of the national flag of the Philippines alt
Russia
A graphic of the flag of Russia alt
Switzerland
A graphic of the flag of Switzerland alt
German
English
French
United Kingdom
A graphic of the national flag of the U.K. alt
United States
A graphic of the flag of the United States of America alt
Uruguay
A graphic of the national flag of Uruguay alt
Venezuela
A graphic of the flag of Venezuela alt
Share

Our Mission to End HIV

Working to make HIV history alt

HIV is one of the world’s greatest health challenges. Nearly 38 million people around the world live with HIV, and 1.5 million newly acquire HIV each year. Johnson & Johnson has been working for 25 years to fight the disease.

Over this time, we’ve developed nine HIV medicines. These drugs allow people to live with HIV as a chronic condition rather than the death sentence it once was. We’re also currently working on a vaccine to prevent HIV, which is now being evaluated in a large-scale efficacy clinical trial.

None of this would be possible without the numerous partners we’ve worked with for the past quarter century: doctors, nurses, patients, advocacy groups, health authorities, NGOs and industry leaders. No one can do it alone. That’s why we also sponsor more than 100 HIV programs in 50 countries. They help educate, support and care for the men, women and children living with HIV who otherwise would be alone.

We won’t stop until we make HIV history.

Innovation
40 Years of HIV
How Johnson & Johnson has pioneered in the battle against HIV/AIDS
Read the Story

“The Road to a Vaccine”: How Lessons Learned in Fighting HIV Help Us Battle COVID-19

In this special episode, journalist and host Lisa Ling interviews top HIV advocates including actress Laverne Cox, Johnson & Johnson Chief Scientific Officer, Dr. Paul Stoffels and more, on the needs of the HIV community, why the development of an HIV vaccine remains essential, and how the learnings over the past 30 years from the quest for an HIV vaccine are being applied to accelerate the development of COVID-19 vaccines. Learn more.

Nurses on the Front Lines

Woman shows dapivirine ring to three young women alt Woman shows dapivirine ring to three young women
This Ring May Just Help Protect Women Against HIV
This Ring May Just Help Protect Women Against HIV
How MenStar's MINA Campaign is Meeting the Needs of Men in the HIV Epidemic
How MenStar's MINA Campaign is Meeting the Needs of Men in the HIV Epidemic
How Drones Are Being Used to Deliver Lifesaving HIV Drugs to Remote Areas of the World
How Drones Are Being Used to Deliver Lifesaving HIV Drugs to Remote Areas of the World
Read the Story
The Sky’s the Limit: Drones Delivering HIV Supplies in Remote Uganda
The Sky’s the Limit: Drones Delivering HIV Supplies in Remote Uganda
Learn More
"1.5 Million Children Are Living With HIV in Sub-Saharan Africa. I'm One of the Doctors Treating These Young Patients Every Day"
"1.5 Million Children Are Living With HIV in Sub-Saharan Africa. I'm One of the Doctors Treating These Young Patients Every Day"
How the New Horizons Collaborative is Transforming Pediatric HIV in Uganda
How the New Horizons Collaborative is Transforming Pediatric HIV in Uganda
How Johnson & Johnson Has Pioneered in the Battle Against HIV/AIDS
How Johnson & Johnson Has Pioneered in the Battle Against HIV/AIDS
An Open Letter from Macaya Douoguih, M.D., M.P.H., on Systemic Racism and Health Disparities
An Open Letter from Macaya Douoguih, M.D., M.P.H., on Systemic Racism and Health Disparities
Read the Letter
Positively Fearless: A Community That's Redefining What It Means to Live with HIV
Positively Fearless: A Community That's Redefining What It Means to Live with HIV
Learn More
HIV & AIDS activists Macaya Douoguih, M.D., MPH, actress Laverne Cox and Matshediso (Tshedi) Sibande alt HIV & AIDS activists Macaya Douoguih, M.D., MPH, actress Laverne Cox and Matshediso (Tshedi) Sibande
Meet 3 Inspiring Women Who Are as Committed as Ever to Making HIV History
Meet 3 Inspiring Women Who Are as Committed as Ever to Making HIV History
Read the Story
Community Health Workers: How Community-Driven Advocacy Changes COVID-19 and Health Decision-Making for the Long Haul
Community Health Workers: How Community-Driven Advocacy Changes COVID-19 and Health Decision-Making for the Long Haul
Learn More

Champions of Science

Quote icon (top)

We’re proud to have played a role in bringing forward nine medicines for people living with HIV, redefining what it means to live with this virus and advancing our mission to make HIV history.

— James Merson, Ph.D., Global Therapeutic Area Head, Infectious Diseases, Janssen Research & Development
Quote icon (bottom)
Quote icon (top)

Our vision is a world without HIV. That’s why we are committed to bringing forward new prevention options that are needed to help stop the global HIV epidemic in its tracks.

— Penny Heaton, M.D., Global Therapeutic Area Head, Vaccines, Janssen Research & Development
Quote icon (bottom)
Quote icon (top)

Our commitment is unwavering, and we remain dedicated to ushering in new advancements in prevention and therapy for the HIV community. Together, we’re helping to build a world without HIV and we won't stop until we make HIV history.

— Brian Woodfall, M.D., Vice President, Global Head of Development, Janssen Infectious Diseases & Vaccines
Quote icon (bottom)
Quote icon (top)

Developing a preventive vaccine for HIV is our top priority and we need armies of people to help make it happen. People in the sciences, people in clinical centers to execute these trials and volunteers—especially volunteers. I’m so impressed with the people who are helping move human health forward.

— Hanneke Schuitemaker, Ph.D., Vice President and Global Head of Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines & Prevention B.V.
Quote icon (bottom)
Quote icon (top)

For decades, the Johnson & Johnson Foundation has partnered with local organizations to equip health workers with specialized training, education and novel technologies to support people living with HIV and help prevent future infections.

— Kris Sterkens, Company Group Chairman, EMEA, Janssen and Chair of the Johnson & Johnson Foundation
Quote icon (bottom)

Addressing the Needs of the World’s Most Vulnerable Populations

Our Global Public Health team is working with partners like PEPFAR, EGPAF, Global Fund and others in those countries hardest hit by HIV.

Stories: People and Progress

Our Latest HIV News

Innovation
March 29, 2022
U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen
Innovation
March 24, 2022
U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting Injectable HIV Treatment
Innovation
February 01, 2022
U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment
Innovation
December 01, 2021
This Ring May Just Help Protect Women Against HIV
Our Company
December 01, 2021
World AIDS Day 2021: How Far We’ve Come, and Yet to Go
Innovation
November 30, 2021
How MenStar's MINA Campaign is Meeting the Needs of Men in the HIV Epidemic
Our Company
August 31, 2021
Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
Innovation
July 26, 2021
The Sky’s the Limit: Drones Delivering HIV Supplies in Remote Uganda
Innovation
July 22, 2021
How Drones Are Being Used to Deliver Lifesaving HIV Drugs to Remote Areas of the World
Personal Stories
July 19, 2021
"1.5 Million Children Are Living With HIV in Sub-Saharan Africa. I'm One of the Doctors Treating These Young Patients Every Day"
Our Company
July 15, 2021
How the New Horizons Collaborative is Transforming Pediatric HIV in Uganda
Innovation
June 01, 2021
How Johnson & Johnson Has Pioneered in the Battle Against HIV/AIDS
Our Company
March 06, 2021
Janssen Announces 96-week Results of Phase 3b Study Demonstrating the Continued Safety and Efficacy of Long-acting HIV Treatment of Rilpivirine and Cabotegravir
Innovation
January 21, 2021
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
Innovation
December 21, 2020
Janssen Announces European Commission Authorisation of the First Complete Long-Acting Injectable HIV Treatment in Europe
Innovation
October 16, 2020
Janssen Receives Positive CHMP Opinion for Long-Acting Regimen for the Treatment of HIV
Innovation
March 20, 2020
Janssen Announces Health Canada Approval of CABENUVA™, the First Long-Acting Regimen for the Treatment of HIV
Innovation
March 11, 2020
Janssen Announces 48-week Results of Phase 3b Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment of Rilpivirine and Cabotegravir Administered Every Two Months
Our Company
October 04, 2019
Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis
Innovation
September 04, 2019
Johnson & Johnson Expands First-of-its-Kind Pediatric HIV Program to Zimbabwe
Innovation
July 23, 2019
Johnson & Johnson Announces New Clinical Data on Mosaic-based HIV Preventive Vaccine Regimen

How We’re Working to Make HIV History

Dr. Paul Janssen Begins Screening Anti-HIV Compounds

The late Dr. Paul Janssen and the Janssen Research Foundation begin a new partnership with the Rega Institute to screen anti-HIV compounds.

Clinical Development Begins

The Janssen Research Foundation moves its first compound for the treatment of HIV into clinical development.

Janssen Partners With Tibotec

The Janssen Research Foundation signs a five-year agreement with Tibotec and founder Dr. Rudi Pauwels to continue the quest for better HIV inhibitors. A year later, Dr. Paul Stoffels co-founds Virco with Dr. Pauwels.

Johnson & Johnson Acquires Tibotec-Virco NV, Belgian Pharmaceutical R&D Company

The company becomes part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and begins late-stage trials on a breakthrough medicine.

Janssen’s First HIV Medicine Receives U.S. FDA Accelerated Approval

Janssen’s next-generation protease inhibitor is granted accelerated approval by the U.S. Food and Drug Administration (FDA) prior to finishing Phase III trials.

Janssen’s Second HIV Medicine Granted Accelerated Approval by U.S. FDA

Janssen’s next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) is approved for use in combination with other antiretroviral medicines for patients with established resistance to other drugs.

Johnson & Johnson Introduces Third HIV Medication

Janssen’s third HIV medication, a next-generation NNRTI, is approved by the U.S. FDA. The company partners with Gilead and then ViiV Healthcare to create a single-tablet, multi-drug HIV regimen based on this NNRTI.

First-of-Its-Kind Drug Donation Program for Pediatric HIV Launched

Janssen announces it will donate two of its HIV medicines, including child-friendly formulations, free of charge to eligible countries in sub-Saharan Africa.

Johnson & Johnson Launches New Horizons Collaborative

Johnson & Johnson and its partners launch the New Horizons Collaborative in sub-Saharan Africa to improve access and scale-up of pediatric HIV treatment. The program is later expanded to 11 total countries.

Janssen Announces Collaboration With Gilead to Develop Single-Tablet Regimen

Janssen and Gilead collaborate in the clinical development of a once daily, single-tablet regimen containing Janssen’s protease inhibitor for the treatment of people living with HIV.

Imbokodo Trial Launches in Southern Africa

The Phase 2b efficacy trial of Janssen’s investigational preventive HIV vaccine regimen begins. The study goes on to enroll over 2,600 young women in Malawi, Mozambique, South Africa, Zambia and Zimbabwe.

First Single-Tablet, Complete Two-Drug Regimen Approved by U.S. FDA

A new treatment comprised of medicines developed by ViiV Healthcare and Janssen is approved as a once-daily regimen, offering a new and simplified option for people living with HIV.

Johnson & Johnson Launches Youth-Led DREAMS Thina Abantu Abasha Program

Johnson & Johnson, joined by the United Nations Population Fund, launch the initiative to promote empowerment and HIV prevention education among adolescent girls and young women in sub-Saharan Africa.

Global Partners Pledge Over $1.2 Billion to Launch the MenStar Coalition

Johnson & Johnson joins Sir Elton John; Prince Harry, Duke of Sussex; and other global partners to support the launch of the MenStar Coalition to expand diagnosis and treatment of HIV in men.

U.S. FDA Approves First Single Tablet Regimen Containing a Protease Inhibitor for the Treatment of HIV

Johnson & Johnson’s once-daily single-tablet regimen is approved by the U.S. FDA, offering a new treatment option for adults living with HIV.

Johnson & Johnson Commits $500 Million to Help End HIV and Tuberculosis

Johnson & Johnson announces four-year commitment, focused on developing new innovations and accelerating the delivery of existing and new tools to combat both epidemics.

Mosaico Vaccine Trial Enrolls First Participant

The Phase 3 trial launches to test the efficacy of Janssen’s investigational preventive HIV vaccine regimen among transgender individuals and cisgender men who have sex with men in the Americas and Europe.

WHO Recommends IPM’s Vaginal Ring for the Prevention of HIV

The world’s first long-acting, discreet HIV prevention option for women, developed by the International Partnership for Microbicides under an exclusive license from Janssen, is recommended for use by the WHO.

European Commission Authorizes the First Long-Acting Injectable Regimen

The European Commission authorizes the world’s first long-acting injectable treatment regimen for HIV, which was co-developed by Johnson & Johnson and ViiV Healthcare.

Janssen Announces Positive Long-Term Data for Every Two Months Long-Acting Injectable Regimen

Positive 96-week data presented by Janssen on the long-acting, injectable treatment regimen demonstrates the efficacy the regimen over a six-times-per-year dosing schedule.

June 1985

October 1990

June 1994

April 2002

June 2006

January 2008

May 2011

December 2013

September 2014

December 2014

November 2017

November 2017

May 2018

July 2018

July 2018

October 2019

November 2019

December 2020

December 2020

March 2021

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue